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Recently, G protein-coupled receptors activated solely by syn-
thetic ligands (RASSLs) have been introduced as new tools to study
Gi signaling in vivo (1, 2). Also, Gs-coupled G protein-coupled
receptors have been engineered to generate Gs-coupled RASSLs
(3, 4). In this study, we exploited the differences in binding pockets
between different classes of H1 receptor agonists and identified the
firstGq/11-coupledRASSL.Themutant humanH1 receptor F435A
(6.55) combines a strongly decreased affinity (25-fold) and potency
for the endogenous ligand histamine (200-fold) with improved
affinities (54-fold) and potencies (2600-fold) for 2-phenylhista-
mines, a synthetic class of H1 receptor agonists. Molecular dynam-
ics simulations provided a mechanism for distinct agonist binding
to both wild-type and F435A mutant H1 receptors.
Receptors activated solely by synthetic ligands (RASSLs)2 have
recently been developed as tools to control G protein signaling in vivo
(5). RASSLs are G protein-coupled receptors (GPCRs) that no longer
respond to their endogenous ligands but can still be activated by syn-
thetic ligands (5). Given the biological importance of GPCRs, the ability
to stimulate a single G protein pathway in a tissue of choice in vivo is
useful for the understanding of subsequent changes in downstream sig-
naling. The use of RASSLs has already provided valuable insight into the
effect of Gi signaling in the heart. Stimulation of a Gi-coupled RASSL
selectively expressed in the murine heart resulted in a strong (3-fold)
and rapid (within 1min after drug administration) decrease in heart rate
(1). In the future, RASSLsmay further be applied, e.g. to create reversible
models of disease states, or combinedwithmicroarrays, to result in gene
expression fingerprints of specific G protein pathways (for review, see
Ref. 6).
There are four major classes of G proteins, named after their respec-
tive -subunit (Gs, Gi, Gq/11, and G12). Each class couples to spe-
cific signal transduction pathways, which are well characterized in vitro
(for a review, see Ref. 7). The first described RASSL couples throughGi
proteins (5) and thus far is the only RASSL being applied in vivo (1, 2, 8).
Also, more recently, several Gs-coupled RASSLs have been developed
(3, 4). Thus far, there have been no reports about either Gq/11- or
G12-coupled RASSLs.
The human histamine H1 receptor (H1R) couples through Gq/11
proteins and thereby activates phospholipase C, resulting in, for exam-
ple, inositol phosphate hydrolysis and increased concentrations of
intracellular Ca2 (9, 10). We previously demonstrated that the H1
receptor also activates NF-B, both in a ligand-induced as well as in a
constitutive manner, via Gq/11 proteins (11). Although several Gq-
coupled GPCRs also activate G12 (for a review, see Ref. 12), the H1R
does not seem to couple to G12 (10, 11, 13).
By mutational analysis, we previously characterized several amino
acids that are involved in the binding of histamine and several synthetic
agonists, such as the histaprodifens (a new class of specificH1R agonists)
(14). Mutation of Phe435 (6.55) to Ala in TM6 (transmembrane domain
6) resulted in a strong decrease in affinity and potency of histamine,
whereas only marginally affecting affinities and potencies of histaprod-
ifens. In this study, we showed that for another class of H1R agonists, the
substituted 2-phenyl-histamines (PheHAs, Ref. 15), mutation of F435A
results in strongly increased affinities and potencies, thereby identifying
the first Gq/11-coupled RASSL.
EXPERIMENTAL PROCEDURES
Materials—pNF-B-Luc was obtained from Stratagene (La Jolla,
CA). ATP disodium salt, bovine serum albumin, chloroquine diphos-
phate, DEAE-dextran (chloride form), histamine dihydrochloride,
mepyramine (pyrilaminemaleate), glycerol, Triton X-100, and polyeth-
yleneimine were purchased from Sigma. D-Luciferin was obtained from
Duchefa Biochemie BV (Haarlem, The Netherlands). Cell culture
media, penicillin, and streptomycin were obtained from Invitrogen.
Fetal bovine serum was obtained from Integro B. V. (Dieren, The Nether-
lands). Cell culture plastics were obtained from Corning Costar (Corning,
NY). [3H]Mepyramine (20 Ci/mmol) was purchased from ICN Biomedi-
cals B. V. (Zoetermeer, The Netherlands). 2-(3-Chlorophenyl)histamine,
2-(3,4-dichlorophenyl)histamine, 2-(cyclohexyl)-histamine, 2-(methyl-
cyclohexyl)-histamine, and 2-(ethylcyclohexyl)-histamine were syn-
thesized at the Vrije Universiteit Amsterdam, The Netherlands.
Gifts of 2-(3-trifluoromethyl)phenylhistamine dihydrogenmaleate
(Dr. W. Schunack), pcDEF3 (Dr. J. Langer, Ref. 16), and the cDNA
encoding the human H1 receptor (Dr. H. Fukui, Ref. 17) are greatly
acknowledged.
Cell Culture and Transfection—COS-7African greenmonkey kidney
cells were maintained at 37 °C in a humidified 5% CO2, 95% air atmo-
sphere in Dulbecco’s modified Eagle’s medium containing 50 IU/ml
penicillin, 50 g/ml streptomycin, and 5% (v/v) fetal bovine serum.
COS-7 cells were transiently transfected using the DEAE-dextran
method as described previously (11).
Site-directed Mutagenesis—The cDNA encoding the human H1R
(17) was subcloned in the pAlter plasmid (Promega), and point muta-
tions were created according to the manufacturer’s protocol (Altered
Sites II, Promega). cDNA of all mutant and wild-type receptors were
subcloned into the expression plasmid pcDEF3 (16). Mutations in the
* The costs of publication of this article were defrayed in part by the payment of page
charges. This articlemust therefore be herebymarked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
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ClPheHA, 2-(3-chlorophenyl)histamine; Cl2PheHA, 2-(3,4-dichlorophenyl)histamine;
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cDNA were verified by DNA sequencing using the dideoxy chain ter-
mination method.
NF-B Reporter Gene Assay—Cells transiently co-transfected with
pNF-B-Luc (125 g/1  107 cells) and pcDEF3 containing mutant or
wild-type humanH1R cDNA (25g/1  107 cells) were seeded in 96-well
white plates (Costar) in serum-free culture medium and incubated with
drugs. After 48 h, cells were assayed for luminescence by aspiration of
themedium and the addition of 25l/well luciferase assay reagent (0.83
mM ATP, 0.83 mM D-luciferin, 18.7 mM MgCl2, 0.78 M Na2H2P2O7,
38.9 mM Tris (pH 7.8), 0.39% (v/v) glycerol, 0.03% (v/v) Triton X-100,
and 2.6 M dithiothreitol). After 30 min, luminescence was measured
for 3 s/well in a Victor2 (Wallac).
Histamine H1R Binding Studies—The transfected COS-7 cells used
for radioligand binding studies were harvested after 48 h and homoge-
nized in ice-cold 50 mM Na2/K phosphate buffer (pH  7.4) (binding
buffer). The COS-7 cell homogenates were incubated for 30 min at
30 °C in H1R binding buffer in 200 l with 3 nM [3H]mepyramine. The
nonspecific binding was determined in the presence of 1 Mmianserin.
The incubations were stopped by rapid dilution with 3 ml of ice-cold
H1R binding buffer. The bound radioactivity was separated by filtration
through Whatman GF/C filters that had been treated with 0.3% poly-
ethylenimine. Filters were washed twice with 3 ml of H1R binding
buffer, and radioactivity retained on the filters was measured by liquid
scintillation counting. Binding datawere evaluated by a non-linear, least
squares curve-fitting procedure using GraphPad Prism® (GraphPad
Software, Inc., San Diego, CA).
Analytical Methods—Protein concentrations were determined
according to Bradford (18), using bovine serum albumin as a standard.
All data shown are expressed as means  S.E. Statistical analyses were
carried out by non-paired Student’s t test. p values 0.05 were consid-
ered to indicate a significant difference (a, p 0.05; b, p 0.01; c, p
0.001).
Molecular Modeling—Our H1R homology model was obtained using
the bovine rhodopsin crystal structure (Protein Data Bank entry 1L9H,
Ref. 19) as the template. The third intracellular loop that connects trans-
membranes 5 and 6 was omitted due to its large size. Side chains were
added using the homology module of InsightII (20). Water molecules
present in the crystal structure were not incorporated. The initial model
was refined by a steepest descent energy minimization. The minimized
model was placed in a dodecahedral box filled with simple point charge
water (21), and a second minimization step using steepest descent was
performed. Hereafter, a 20-ps molecular dynamics (MD) run was per-
formed with positions restraints (1000 kJ  mol1 nm2) on all heavy
protein atoms. Finally, the model was refined by a 100-ps MD run. In
this structure, Phe435 was changed to Ala with InsightII, thus creating a
model of the F435A H1R.
Histamine and 2-(3-chlorophenyl)histamine (ClPheHA) were
docked in theWT and F435Amodels using AutoDock 3.0.0 (22) apply-
ing default parameters. The monocationic ligands were assigned Lo¨w-
din atomic charges obtained after a single point ab initio restricted
Hartree-Fock calculation using 6-31Gr* with the GAMESS US package
(23). The protein was assigned with KOLLUA partial charges using the
SYBYL program (version 6, Tripos, St. Louis). Only essential hydrogens
were taken into account.
The obtained ligand-receptor complexes were minimized using the
steepest descentmethod. These ligand-receptor complexes were placed
in a dodecahedral box, with aminimumdistance of 7 Å between protein
and the box. The system was solvated with simple point charge water,
and the protein partial charges were assigned by GROMACS.
Again, a steepest descent procedure was performed on the system.
Subsequently, a set of MD runs with position restraints (1000 kJ
mol1nm2) was applied to the system in which a controlled release of
the restraints was performed. A run for 50 ps with position restraints on
all heavy protein atoms and all ligand atoms was performed, with the
protein hydrogens and all watermolecules unrestrained. Consecutively,
a run was performed for 20 ps with position restraints on all C-atoms,
all heavy atoms of residues Asp107 and Asn198, and all ligand atoms.
Finally, a MD run was performed for 1 ns with only position restraints
on C-atoms. During the last 500 ps of this run, the presence of hydro-
gen bonds was analyzed using cutoff distance between heavy atoms of
3.5 Å and a cutoff angle between acceptor donor and hydrogen of 60°.
All minimizations and MD simulations were performed using the
GROMACS software package and the GROMOS 43a1 force field (24,
25) and LINCS constraints (26) on all bonds. An NPT ensemble was
generated using both the Berendsen thermostat and the barostat with
default settings for 300 K and 1 bar (25).
RESULTS
Mutation F435ADifferentiallyModulates Affinities of Several Classes
of H1RAgonists—At theH1R, severalH1R agonists show a higher affinity
than the natural agonist histamine. The histamine analogs 2-(3-triflu-
oromethyl-phenyl)histamine (CF3PheHA), histaprodifen, suprahistap-
rodifen, and the newly characterized H1R agonist 8R-lisuride bind
9–1000-fold better to the H1R as compared with histamine (TABLE
ONE). Previously, we characterized Phe435 (6.55), as a specific interac-
tion point for histamine (14). Mutation of this residue into alanine
resulted in a 25-fold decrease in histamine affinity without drastic alter-
ations in the affinity of the agonists histaprodifen and suprahistapodifen
TABLE ONE
Affinities of H1R agonists for wild-type and Phe
435 Alamutant H1Rs
a Affinities are determined by [3H]mepyramine displacement. All data are calculated as the mean S.E. of at least three experiments, each performed in triplicate.
b p 0.01.
c p 0.001 vs.WTH1R.
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(TABLE ONE) (Ref. 14). In this study, we further studied the role of
Phe435 (6.55) in agonist binding to the H1R. TABLE ONE shows that,
similar to histaprodifen and suprahistaprodifen, affinities of pyridyleth-
ylamine as well as 8R-lisuride are comparable for WT and F435A
mutant H1Rs. Unexpectedly, for F435A H1R, the affinity of CF3PheHA
was increased 54-fold as compared with WT H1R (Fig. 1 and TABLE
ONE). Thus, the F435A mutant H1R has an affinity for CF3PheHA that
exceeds the affinity of histamine more than 10,000-fold.
Basic Characterization of Phe435 Mutant H1Rs—Phenylalanine at
position 6.55 is conserved among all knownH1Rs (27) and is implicated
in ligand binding in both human and guinea pig H1Rs (14, 28). The
F435A mutation removes an aromatic ring structure from the binding
pocket, and therefore, potential interactions with either ligands or other
amino acids in the H1R-binding pocket may be lost. However, exchang-
ing the bulky Phe435 (6.52)with the smaller alaninemay also increase the
size of the ligand-binding pocket and thus create space for the trifluoro-
methyl-phenyl moiety of CF3PheHA, resulting in an increased affinity
for this ligand. To address the latter possibility, we created additional
mutant H1Rs (F435V and F435L) that vary in the size of the side chain at
position 6.55.
The generated mutant receptors are expressed at comparable levels
(Bmax  13.6–20.1 pmol/mg of protein) in transiently transfected
COS-7 cells and bind the H1R radioligand [3H]mepyramine with virtu-
ally unchanged affinity (Kd 1.5–5.7 nM), as determined by radioligand
saturation binding experiments (TABLE TWO). Although the expres-
sion levels are similar, there is a clear difference in constitutive GPCR
activities of the tested H1R mutants as measured by an NF-B-driven
reporter gene assay (Fig. 2, white bars). Although the basal activity of
H1R F435L H1R is comparable with the WT H1R, the level of constitu-
tiveNF-B activation ofH1R F435V is twice as high, whereas formutant
H1R, F435A constitutive activity is hardly detectable. Although the lev-
els of constitutive NF-B activation vary between the mutant H1Rs,
their agonist-induced responses are comparable (Fig. 2, black bars),
indicating that G protein-coupling of the mutant H1Rs is not impaired.
Binding Analysis of WT and Phe435 Mutant H1Rs—Similar to the
mutant F435A H1R (pKi 2.7), the mutant H1R F435V (pKi 2.9) and
F435L (pKi 2.9) exhibit a strong decrease in their affinity for histamine
as comparedwith theWTreceptor (pKi 4.1) (TABLETHREE). Again,
thesemutant receptors exhibit an increased affinity for CF3PheHA. The
exchange of Phe435 for leucine, valine, or alanine results in mutant H1Rs
with a 47-, 124-, and 54-fold increased affinity for CF3PheHA respec-
tively, as compared with theWT receptor (pKi 5.0) (TABLETHREE).
For these mutant H1Rs, the affinity of CF3PheHA greatly exceeds their
affinity of the endogenous ligand histamine, the mutant F435V H1R
exhibiting the greatest selectivity for the synthetic agonist CF3PheHA
over histamine (17,000-fold).
We tested two other substituted PheHAs, ClPheHA and 2-(3,4-di-
chlorophenyl)histamine (Cl2PheHA), on the mutant H1Rs as well. For
theWTH1R, the affinity of ClPheHA (pKi 5.3) is slightly higher then
than that of CF3PheHA (pKi  5.0). An (additional) para-chloro sub-
stituent is not favorable for H1R affinity (pKi  4.6), fitting previous
findings for both human and rodent H1Rs (29). Similar to CF3PheHA,
the affinity of ClPheHA is increased upon mutation of Phe435 into
leucine (pKi 6.8), valine (pKi 7.3), or alanine (pKi 6.7). Although
for Cl2PheHA, H1R affinities are lower and increases in affinity are
smaller, the same trend upon mutation is observed (pKi values, 4.6, 5.3,
5.8, and 5.4, respectively). Similar to CF3PheHA, for ClPheHA and
Cl2PheHA, mutation F435V also results in the largest increase in affin-
ity, as compared with the WT receptor.
Additionally, we tested a series of 2-cyclohexyl-histamines (CxHAs),
varying in spacer length between the imidazole ring and the cyclohexyl
moieties: CxHA, 2-(methyl-cyclohexyl)-histamine (MeCxHA), and
2-(ethyl-cyclohexyl)-histamine (EthCxHA). The affinities of theCxHAs
are approximately equal to the affinity of histamine (TABLE THREE).
Again, mutation of Phe435 into alanine, valine, or leucine results in
increased affinities as compared with the WT H1R (TABLE THREE).
The increases in affinity, however, are smaller (maximum 10-fold) than
those observed for the PheHAs (maximum120-fold). Although changes
in affinity are less prominent, for EthCxHA, we observe a correlation
between the space available in the binding pocket (Ala3Val3 Leu3
Phe) and the affinities for the mutant receptors (F435A, pKi 4.9; F435V,
pKi  4.6; F435L, pKi  4.3; and WT, pKi  4.1, TABLE THREE). For
both CxHA and MeCxHA, the highest affinities are observed for the
F435V mutant H1R, following the trend observed for the PheHAs.
Functional Analysis of WT and Phe435 Mutant H1Rs—Using an
NF-B-driven reporter gene assay, we evaluated the potencies of several
2-phenylsubstituted histamine analogs for mutant and WT H1Rs. For
the WT H1R, these analogs are less potent than the endogenous ligand
histamine (pEC50 6.9) (TABLE THREE). Fig. 3 clearly illustrates that
as compared with theWTH1R, the potency of HA at the H1R F435A is
decreased 200-fold, whereas the potency of ClPheHA is increased
2,600-fold. Also, for CF3PheHA and Cl2PheHA, potencies were
increased upon the mutation F435A; again ClPheHA (pEC50 9.4) and
CF3PheHA (pEC50  9.2) are equipotent, and Cl2PheHA is clearly less
potent (pEC50  7.9) (TABLE THREE). For mutant H1Rs F435L and
F435V, similar trends are observed, with PheHA potencies for H1R
F435Vbeing slightly higher than for F435A andF435LH1Rs. Formutant
H1Rs, F435A, F435V, and F435L ClPheHA and CF3PheHA are agonists
with subnanomolar potencies, which exceed the potency of histamine
70,000–280,000-fold.
Molecular Modeling of WT and F435AMutant H1Rs—Our model of
the H1R, based on the bovine rhodopsin crystal structure, was used to
visualize the interactions of either histamine or ClPheHA with the WT
and F435A mutant H1R. Models of both WT and F435A H1Rs were
optimized by molecular dynamics simulations. Hereafter, histamine
and ClPheHA were automatically docked in both WT and F435A
mutant H1Rmodels. Finally, a second round ofmolecular dynamics was
used to optimize the receptor-ligand complexes. In the WT H1R, both
histamine and ClPheHA show an ionic interaction between the con-
served Asp107 (3.32) in TM3 (transmembrane domain 3) and their eth-
ylamine group over distances of 2.6 and 3.0 Å, respectively (Fig. 4,A and
C). As expected, differences between histamine and ClPheHA can be
observed for interaction with Phe435. In binding histamine, Phe435 has
FIGURE 1. Displacement of [3H]mepyramine binding to wild-type H1R (closed sym-
bols, solid lines) and to mutant receptor H1R F435A (open symbols, dotted lines)
receptors by histamine (triangles), and 2-(3-trifluoromethyl-phenyl)histamine
(CF3PheHA, circles). A representative experiment is shown.
Mutant H1R F435A, a Gq/11-coupled RASSL
OCTOBER 14, 2005•VOLUME 280•NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 34743
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
an indirect role, keeping Phe432 in an edge-to-face orientation toward
the imidazolemoiety of histamine (Fig. 4A). In this orientation, a hydro-
gen bond can be formed between the distal nitrogen of the imidazole
ring of histamine and Asn198 at a distance of 2.7 Å and is observed
during 47% of the MD simulation. In binding ClPheHA, Phe435 directly
interacts with the ligand by – stacking with the phenyl moiety of
ClPheHA (Fig. 4B). By this interaction, Phe435 prevents hydrogen bond-
ing of the imidazole ring with Asn198 since the distance exceeds 5 Å.
The difference in interaction with Phe435 between histamine and
ClPheHA is further illustrated by observed changes in receptor-ligand
interactions upon the mutation F435A. For histamine, the mutation
F435A releases Phe432, thereby allowing histamine to shift toward
Asp107, resulting in an increased distance between the agonist and
Asn198 (7.0 Å) and the loss of the hydrogen bond between Asn198 and
the imidazole ring of histamine (Fig. 4C). Upon themutation F435A, we
observed an opposite effect for ClPheHA; removal of the – stacking
with Phe435 allows the ligand to move deeper in the binding pocket,
enabling hydrogen bonding of the imidazole ring with Asn198 at a dis-
tance of 2. 4 Å. This hydrogen bond is observed during 78% of the MD
simulation (Fig. 4D).
DISCUSSION
Most H1R agonists are structurally closely related to histamine and
have the imidazole ring either replaced by other heterocycles (pyridyl-
ethylamine, thiozolylethylamine) or substituted at the 2-position
(histaprodifens, PheHAs) (30). Already in 1994, we demonstrated that
H1R agonists, although structurally similar, appear to have different
binding modes (31). Recently, we extended this conclusion to histap-
rodifens. In contrast to histamine, for this class of compounds, interac-
tionswith eitherAsn198 or Phe435 are no longer required for high affinity
H1R binding (14). Asn198, however, still appeared crucial for receptor
activation. To establishwhether the interactionwith Phe435 is specific to
histamine alone, we tested several other H1R agonists for interaction
with Phe435. Comparable with histaprodifen, the affinities of suprahi-
staprodifen, pyridylethlamine, and 8R-lisuride were not altered by the
mutation F435A. For CF3PheHA however, the affinity for H1R F435A
was 54-fold higher than for the WT H1R. Studying receptor-mediated
NF-B activation, the differences in potency ofCF3PheHAbetweenWT
and F435A mutant receptors (1,500-fold) even exceeded the observed
differences in affinity. Similar trends are observed for the 3-chloro-
substituted PheHA (ClPheHA) and to a lesser extent for 3,4-dichloro-
substituted PheHA (dClPheHA). These observations strongly suggested
that despite structural (histamine-like moiety) and/or functional simi-
larity (agonism), the precise orientation ofH1R agonists within theH1R-
binding pocket differs.
We used computer modeling to examine the different H1R binding
modes for histamine and the synthetic agonist ClPheHA. For histamine,
we observed hydrogen bonding between one of the imidazole nitrogens
and Asn198, whereas for ClPheHA, this interaction is not observed in
our molecular dynamics simulations. We previously demonstrated that
interaction with Asn198 appears to be a prerequisite for H1R activation
(14). This explains why although the affinity of histamine for the WT
H1R is lower than that of ClPheHA, histamine is more efficacious as an
H1R agonist.
Our computational studies suggested that uponmutation of Phe435 to
alanine, the aromatic interaction of Phe432 with the imidazole ring of
histamine is lost. Histamine gained in conformational freedom
(entropy) and the distance between Asn198, and the imidazole nitrogen
of histamine increased to 7 Å, suggesting the loss of hydrogen bonding.
The loss of this interaction and the increase in entropy most likely
accounted for the observed decreased in affinity and potency of hista-
mine (as compared with the WT H1R). In contrast, for ClPheHA, the
distance between its imidazole moiety and Asn198 was decreased in the
F435A H1R, enabling hydrogen bonding and thus facilitating both high
affinity binding and potent activation of the F435A H1R.
To delineate the effect of mutating the bulky, aromatic Phe435 to a
FIGURE 2. Basal H1R activation (white bars) andmaximal histamine-induced NF-B
activation (black bars) in COS-7 cells transfectedwith cDNAofWT,mutant H1Rs, or
empty vector (mock). Basal activity ofWT H1R is put at 100%. Values are determined by
NF-B-driven reporter gene assays.
TABLE TWO
Characteristics of [3H]mepyramine binding toWT andmutant H1R
The values are determined by saturation radioligand binding assays. All data are calculated as the mean S.E. of at least three experiments, each performed in
triplicate.
a p 0.01 vs.WT receptor.
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small, aliphatic alanine, mutant H1Rs were created in which the side
chain at this position have intermediate sizes: Phe4353 Leu3 Val3
Ala. For none of the PheHAs did we observe gradual size-dependent
changes in affinity or potency. Instead, increased affinities and potencies
appeared an all-or-nothing phenomenon, correlating with the presence
or absence of the aromatic Phe435. The various mutations also affected
affinities of MeCxHA and CxHA, in a similar but attenuated fashion.
Since we did observe a small but clear correlation between affinity and
side chain bulk at position 6.55 for EthCxHA, having an ethyl chain as a
spacer between histamine and cyclohexyl moieties, we speculated that
only for this ligand, the space in binding pocket is limiting over the full
array of receptors. Potentially, increasing the spacer length between
histamine moiety and (substituted) phenyl ring would also result in
PheHAs that can discriminate between the various mutant H1Rs.
RASSLs areGPCRs that no longer respond to endogenous ligands but
can still be activated by synthetic ligands (5). Previously, such mutant
GPCRs have been introduced as new tools to selectively study specific G
protein pathways in vivo (1). So far, RASSLs for bothGi andGs pathways
have been described (3–5). For mutant receptors F435A, F435V, and
F435L, the affinity and potency of histamine are strongly decreased as
compared with the WT H1R, whereas the affinities and potencies of
PheHAs are strongly increased (TABLE THREE). These mutant recep-
tors can therefore be classified as the first Gq/11-coupled RASSLs. It is
noteworthy that these mutant H1Rs differ in their level of constitutive
NF-B activation. The constitutive activity of H1R F435L was similar to
that of the WT H1R, whereas it is hardly detectable for H1R F435A and
increased for H1R F435V. Since mutant receptors F435L and F435V
displayed basal NF-B activation, they are not “solely activated by syn-
thetic ligands,” and therefore, onlyH1R F435A fits the criteria of RASSL.
It is important to notice that ligand-independent constitutive activity
of RASSLS can be apparent in vivo. Chronic overexpression of Ro1, a
Gi-coupled RASSL, in transgenic mice caused mortality, independent
of stimulation with the synthetic agonist (2). This mortality could be
blocked by treatment with either the specific Gi-blocker pertussis toxin
FIGURE 3. Representative dose response curves
of histamine (A) and ClPheHA (B) for wild-type
H1R (E) and mutant receptor H1R F435A (●) as
measured by NF-B activation.
TABLE THREE
Characterization of H1R agonists on wild-type andmutant H1Rs
Potencies of agonists (pEC50) are determined by an NF-B-driven reporter gene assay. Affinities are determined by [3H]mepyramine displacement. All data are
calculated as the mean S.E. of at least three experiments, each performed in triplicate. ND indicates that the value could not be determined.
a p 0.05.
b p 0.01.
c p 0.001 vs.WT receptor.
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or the Ro1 antagonist nor-binaltorphimine (2). Apparently, constitutive
Ro1-signaling was accountable for this mortality, and this receptor was
not a real RASSL. For the F435A-RASSL, we believe that no constitutive
activity-related side effects can be expected since, even at receptor
expression levels exceeding 10 pmol/mg, no basal NF-B signaling is
observed using a sensitive reporter gene assay. Besides our Gq/11-cou-
pled RASSL (H1R F435A), H1R F435L may also be useful for future in
vivo use.When replacing the endogenous H1R, it would create a knock-
out system, displaying the H1R-like constitutive signaling but lacking
histamine-induced responses. One would, however, still be able to
induce H1R responses by administration of synthetic agonists.
The in vivo use of the RASSL Ro1 has generated considerable knowl-
edge on the effect of Gi signaling on heart rate (1) and cardiomyopathy
(2). Currently, the Ro1 has also been expressed in other tissues of trans-
genicmice, including several brain areas, to further address the effects of
Gi signaling (6). At this moment, much less is known about in vivo
effects of Gq/11 stimulation. Our current Gq/11-coupled RASSL may
be employed to fill that gap of in vivo knowledge. Although the H1R
RASSL can still be stimulated by the endogenous ligand histamine at
high concentrations, plasma levels of histamine in healthy humans, rats,
or rabbits are well below that level (2–250 nM) (32–35). When in vivo
application is limited to tissues in which histamine concentrations are
not exceptionally high, potentially excluding, for example, brain (syn-
aptic histamine) and immune system (mast cell contents), the H1R
RASSL is expected to remain quiescent until stimulation with synthetic
agonists. Future research should focus on further modifications of our
RASSL to make it even less responsive to histamine.
In conclusion, we exploited subtle differences in the binding pockets
for different classes of H1R agonists and showed that the precise orien-
tation of histamine and 2-phenylhistamine in the binding pocket is quite
different. As a result, we have thus identified H1R F435A (6.55) as the
first Gq/11-coupled RASSL. This mutant H1R combines strongly
decreased affinities and potencies for the endogenous ligand histamine
with improved affinities and potencies for PheHAs, a synthetic class of
H1R agonists. In contrast to mutant H1Rs F435V and F435L, this recep-
tor lacks constitutive activity, which is a characteristic, we believe, that
should be emphasized more strongly in the development of future
RASSLs.
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